L19-IL2 is an immunocytokine composed of an scFv specific for the angiogenesis-associated B-fibronectin (B-FN) isoform and IL2 (interleukin 2) selectively accumulated on tumor neovasculature, and showed a good anti-tumor activity in preclinical models and PhaseI/II clinical trials, both in solid and hematological tumors [37,38,39,40]. Here, IL2 is linked to neoplasm.